Bristol-Myers Squibb vs McKesson
Bristol-Myers Squibb (BMY), health care, and McKesson (MCK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bristol-Myers Squibb and McKesson are valued at about the same: $124.7B and $127B. Bristol-Myers Squibb trades at 13.5 times earnings and McKesson at 28.4. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and McKesson's +28.4%.
Key facts
- Bristol-Myers Squibb market value
- $124.7B
- McKesson market value
- $127B
- Bristol-Myers Squibb P/E
- 13.5
- McKesson P/E
- 28.4
- Bristol-Myers Squibb revenue
- $48.2BFY to 2025-12-31
- McKesson revenue
- $403.4BFY to 2026-03-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Bristol-Myers Squibb | McKesson |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $124.7Blower | $127Bhigher |
| Revenue | $48.2Blower | $403.4Bhigher |
| Earnings | $7.1Bhigher | $4.8Blower |
| Employees | 32,500lower | 41,600higher |
| Total assets | $90Bhigher | $82.3Blower |
| Valuation | ||
| P/E | 13.5lower | 28.4higher |
| P/S | 2.6higher | 0.3lower |
| P/B | 5.3 | — |
| Dividend yield | 4.00%higher | 0.31%lower |
| Profitability | ||
| Operating margin | — | 1.54% |
| Balance sheet | ||
| Net assets | $18.5Bhigher | -$2.2Blower |
| Total liabilities | $71.5Blower | $83.2Bhigher |
| Total debt | $45.1Bhigher | $6.5Blower |
| Cash on hand | $10.2Bhigher | $4Blower |
| Price change | ||
| Today | -3.08%lower | -0.48%higher |
| 1 year | +33.7%higher | +28.4%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Cliff Asness0.6% / 0.2%
Bristol-Myers Squibb only (14)
- Richard Pzena2.6%
- Thomas Kahn1.6%
- Josef Lakonishok1.1%
- Primecap team1.0%
- Bill Miller (founder)0.9%
- Mark Boyar0.5%
- John Rogers0.4%
- John Overdeck and David Siegel (founders)0.4%
- Tweedy, Browne team0.2%
- Jeremy Grantham (co-founder)0.1%
- Murray Stahl<0.1%
- Mairs & Power team<0.1%
- Rajiv Jain<0.1%
- Sarah Ketterer<0.1%
McKesson only (12)
- Ron Muhlenkamp (founder)5.7%
- Charles Brandes (founder)0.8%
- Frank Sands0.6%
- Paul Tudor Jones0.4%
- Stephen Mandel0.3%
- Jim Simons (1938–2024)0.2%
- David Shaw (founder)0.2%
- Ray Dalio (founder)0.2%
- Ken Griffin0.2%
- Joel Greenblatt0.1%
- Howard Gleicher<0.1%
- Temasek<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / McKesson). Who owns BMY · Who owns MCK
More on Bristol-Myers Squibb
Further comparisons
Bristol-Myers Squibb against its closest peers
McKesson against its closest peers
Learn
Questions and answers
Which is bigger, Bristol-Myers Squibb or McKesson?
By market value, McKesson is the larger: $127B against $124.7B for Bristol-Myers Squibb. By revenue in its latest fiscal year, McKesson is the larger: $403.4B against $48.2B for Bristol-Myers Squibb.
Which has the higher P/E ratio?
McKesson: 28.4, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher dividend yield?
Bristol-Myers Squibb: 4.00%, against 0.31% for McKesson. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Bristol-Myers Squibb: $45.1B, against $6.5B for McKesson. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Bristol-Myers Squibb and McKesson?
In their latest 13F filings, Cliff Asness holds both.
Cite this page
Funkfolio, “Bristol-Myers Squibb vs McKesson”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-mck
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.